Opinion|Videos|July 15, 2024
Treatment Decision Making in first-line combinations for advanced RCC
Author(s)Martin H. Voss, MD, Moshe Ornstein, MD
The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit.
Advertisement
Episodes in this series
- What are the available first-line combination options for advanced RCC?
- Please discuss your rationale for choosing between IO+IO and IO+TKI approaches and review these data: Network meta-analysis (NMA) –
Grunwald, et al. ASCO GU 2024. Abstract 482 – len + pembro vs other 1L treatments in advanced RCC
- How do you approach treatment selection in the frontline setting?
- What factors do you consider when choosing treatment?
- Which patients do you choose len-pembro versus axi-pembro versus cabo-nivo?
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
4
Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026
5